Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells

Experimental Cell Research

Volumn 315, Issue 20, 2009, Pages 3574-3586

  Vi, Linda ^a,b   Feng, Lucy ^a,b   Zhu, Rebecca D ^a,b   Wu, Yan ^a,b   Satish, Latha ^c   Gan, Bing Siang ^a,b,d   O'Gorman, David B ^a,b,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Apoptosis; Cell proliferation; Contraction; Dupuytren's disease; Myofibroblast; Palmar fascia; Periostin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; TRANSCRIPTION FACTOR RUNX2;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DUPUYTREN CONTRACTURE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCLE CONTRACTILITY; MYOFIBROBLAST; NUCLEOTIDE SEQUENCE; PALMAR FASCIA; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; UPREGULATION;

EID: 70449517272     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.07.015     Document Type: Article

References (77)

1. Urban M., Feldberg L., Janssen A., and Elliot D. Dupuytren's disease in children. J. Hand Surg. [Br] 21 (1996) 112-116
2. Gudmundsson K.G., Arngrimsson R., Sigfusson N., Bjornsson A., and Jonsson T. Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study. J. Clin. Epidemiol. 53 (2000) 291-296
3. Saboeiro A.P., Porkorny J.J., Shehadi S.I., Virgo K.S., and Johnson F.E. Racial distribution of Dupuytren's disease in Department of Veterans Affairs patients. Plast. Reconstr. Surg. 106 (2000) 71-75
4. Saar J.D., and Grothaus P.C. Dupuytren's disease: an overview. Plast. Reconstr. Surg. 135-6 (2000) 106,. 125-34;. quiz.
5. Hakstian R. Late Results of Extensive Fasciectomy (1974), Grune and Stratton, New York
6. Norotte G., Apoil A., and Travers V. A ten years follow-up of the results of surgery for Dupuytren's disease. A study of fifty-eight cases. Ann. Chir. Main. 7 (1988) 277-281
7. Jabaley M.E. Surgical treatment of Dupuytren's disease. Hand Clin. 15 (1999) 109-126 vii
8. Mullins P.A. Postsurgical rehabilitation of Dupuytren's disease. Hand Clin. 15 (1999) 167-174 viii
9. Gudmundsson K.G., Arngrimsson R., and Jonsson T. Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren's disease. Scand. J. Rheumatol. 30 (2001) 31-34
10. Kobus K., Wojcicki P., Dydymski T., Wegrzyn M., and Hamlawi F. Evaluation of treatment results of patients with Dupuytren's contracture-our clinical experience. Ortop. Traumatol. Rehabil. 9 (2007) 134-140
11. Rehman S., Salway F., Stanley J.K., Ollier W.E., Day P., and Bayat A. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J. Hand Surg. [Am] 33 (2008) 359-372
12. Qian A., Meals R.A., Rajfer J., and Gonzalez-Cadavid N.F. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 64 (2004) 399-404
13. Shih B., Wijeratne D., Armstrong D.J., Lindau T., Day P., and Bayat A. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. J. Hand Surg. [Am] 34 (2009) 124-136
14. Horiuchi K., Amizuka N., Takeshita S., Takamatsu H., Katsuura M., Ozawa H., Toyama Y., Bonewald L.F., and Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J. Bone Miner. Res. 14 (1999) 1239-1249
15. Nakazawa T., Nakajima A., Seki N., Okawa A., Kato M., Moriya H., Amizuka N., Einhorn T.A., and Yamazaki M. Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J. Orthop. Res. 22 (2004) 520-525
16. Lindner V., Wang Q., Conley B.A., Friesel R.E., and Vary C.P. Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 77-83
17. Erkan M., Kleeff J., Gorbachevski A., Reiser C., Mitkus T., Esposito I., Giese T., Buchler M.W., Giese N.A., and Friess H. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132 4 (2007) 1447-1464
18. Butcher J.T., Norris R.A., Hoffman S., Mjaatvedt C.H., and Markwald R.R. Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase. Dev. Biol. 302 1 (2007) 256-266
19. Forsti A., Jin Q., Altieri A., Johansson R., Wagner K., Enquist K., Grzybowska E., Pamula J., Pekala W., Hallmans G., Lenner P., and Hemminki K. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res. Treat. 101 1 (2007) 83-93
20. Grigoriadis A., Mackay A., Reis-Filho J.S., Steele D., Iseli C., Stevenson B.J., Jongeneel C.V., Valgeirsson H., Fenwick K., Iravani M., Leao M., Simpson A.J., Strausberg R.L., Jat P.S., Ashworth A., Neville A.M., and O'Hare M. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res. 8 (2006) R56
21. Kudo Y., Ogawa I., Kitajima S., Kitagawa M., Kawai H., Gaffney P.M., Miyauchi M., and Takata T. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res. 66 (2006) 6928-6935
22. Tai I.T., Dai M., and Chen L.B. Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies. Carcinogenesis 26 (2005) 908-915
23. Siriwardena B.S., Kudo Y., Ogawa I., Kitagawa M., Kitajima S., Hatano H., Tilakaratne W.M., Miyauchi M., and Takata T. Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br. J. Cancer 95 (2006) 1396-1403
24. Sasaki H., Dai M., Auclair D., Fukai I., Kiriyama M., Yamakawa Y., Fujii Y., and Chen L.B. Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas. Cancer 92 (2001) 843-848
25. Sasaki H., Dai M., Auclair D., Kaji M., Fukai I., Kiriyama M., Yamakawa Y., Fujii Y., and Chen L.B. Serum level of the periostin, a homologue of an insect cell adhesion molecule, in thymoma patients. Cancer Lett. 172 (2001) 37-42
26. Sasaki H., Lo K.M., Chen L.B., Auclair D., Nakashima Y., Moriyama S., Fukai I., Tam C., Loda M., and Fujii Y. Expression of periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn. J. Cancer Res. 92 (2001) 869-873
27. Shao R., Bao S., Bai X., Blanchette C., Anderson R.M., Dang T., Gishizky M.L., Marks J.R., and Wang X.F. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol. Cell. Biol. 24 (2004) 3992-4003
28. Gillan L., Matei D., Fishman D.A., Gerbin C.S., Karlan B.Y., and Chang D.D. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 62 (2002) 5358-5364
29. Bao S., Ouyang G., Bai X., Huang Z., Ma C., Liu M., Shao R., Anderson R.M., Rich J.N., and Wang X.F. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5 (2004) 329-339
30. Carter A.M., Nygard K., Mazzuca D.M., and Han V.K. The expression of insulin-like growth factor and insulin-like growth factor binding protein mRNAs in mouse placenta. Placenta 27 (2006) 278-290
31. Han V.K., Matsell D.G., Delhanty P.J., Hill D.J., Shimasaki S., and Nygard K. IGF-binding protein mRNAs in the human fetus: tissue and cellular distribution of developmental expression. Horm. Res. 45 (1996) 160-166
32. Tomasek J., and Rayan G.M. Correlation of alpha-smooth muscle actin expression and contraction in Dupuytren's disease fibroblasts. J. Hand. Surg. [Am] 20 (1995) 450-455
33. Dallon J.C., and Ehrlich H.P. A review of fibroblast-populated collagen lattices. Wound Repair Regen. 16 (2008) 472-479
34. Gabbiani G., and Majno G. Dupuytren's contracture: fibroblast contraction? An ultrastructural study. Am. J. Pathol. 66 (1972) 131-146
35. Tomasek J.J., Schultz R.J., Episalla C.W., and Newman S.A. The cytoskeleton and extracellular matrix of the Dupuytren's disease "myofibroblast": an immunofluorescence study of a nonmuscle cell type. J. Hand Surg. [Am] 11 (1986) 365-371
36. Magro G., Fraggetta F., Travali S., and Lanzafame S. Immunohistochemical expression and distribution of alpha2beta1, alpha6beta1, alpha5beta1 integrins and their extracellular ligands, type IV collagen, laminin and fibronectin in palmar fibromatosis. Gen. Diagn. Pathol. 143 (1997) 203-208
37. Baril P., Gangeswaran R., Mahon P.C., Caulee K., Kocher H.M., Harada T., Zhu M., Kalthoff H., Crnogorac-Jurcevic T., and Lemoine N.R. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta(4) integrin and the PI3k pathway. Oncogene 26 14 (2007) 2082-2094
38. Tse R., Howard J., Wu Y., and Gan B.S. Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-beta2. BMC Musculoskelet. Disord. 5 (2004) 41
39. Luck J.V. Dupuytren's contracture; a new concept of the pathogenesis correlated with surgical management. J. Bone Joint Surg. Am. 635-64 (1959) 41-A.
40. Hurst L.C., Badalamente M.A., and Makowski J. The pathobiology of Dupuytren's contracture: effects of prostaglandins on myofibroblasts. J. Hand Surg. [Am] 11 (1986) 18-23
41. Iwasaki H., Muller H., Stutte H.J., and Brennscheidt U. Palmar fibromatosis (Dupuytren's contracture). Ultrastructural and enzyme histochemical studies of 43 cases. Virchows. Arch. A. Pathol. Anat Histopathol. 405 (1984) 41-53
42. Rayan G.M., Parizi M., and Tomasek J.J. Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro. J. Hand Surg. [Am] 21 (1996) 1065-1070
43. Rayan G.M., and Tomasek J.J. Generation of contractile force by cultured Dupuytren's disease and normal palmar fibroblasts. Tissue Cell 26 (1994) 747-756
44. Dave S.A., Banducci D.R., Graham III W.P., Allison G.M., and Ehrlich H.P. Differences in alpha smooth muscle actin expression between fibroblasts derived from Dupuytren's nodules or cords. Exp. Mol. Pathol. 71 (2001) 147-155
45. Seyhan H., Kopp J., Schultze-Mosgau S., and Horch R.E. Increased metabolic activity of fibroblasts derived from cords compared with nodule fibroblasts sampling from patients with Dupuytren's contracture. Plast. Reconstr. Surg. 117 (2006) 1248-1252
46. Bisson M.A., McGrouther D.A., Mudera V., and Grobbelaar A.O. The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1. J. Hand Surg. [Br] 28 (2003) 351-356
47. Norris R.A., Damon B., Mironov V., Kasyanov V., Ramamurthi A., Moreno-Rodriguez R., Trusk T., Potts J.D., Goodwin R.L., Davis J., Hoffman S., Wen X., Sugi Y., Kern C.B., Mjaatvedt C.H., Turner D.K., Oka T., Conway S.J., Molkentin J.D., Forgacs G., and Markwald R.R. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J. Cell. Biochem. 101 3 (2007) 695-711
48. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell. Biol. 130 (1995) 503-506
49. Bornstein P. Matricellular proteins: an overview. Matrix Biol. 19 (2000) 555-556
50. Bornstein P., and Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14 (2002) 608-616
51. Norris R.A., Borg T.K., Butcher J.T., Baudino T.A., Banerjee I., and Markwald R.R. Neonatal and adult cardiovascular pathophysiological remodeling and repair: developmental role of periostin. Ann. N.Y. Acad. Sci. 1123 (2008) 30-40
52. Hamilton D.W. Functional role of periostin in development and wound repair: implications for connective tissue disease. J. Cell Commun. Signal 2 1-2 (2008) 9-17
53. Boudreau N.J., and Jones P.L. Extracellular matrix and integrin signalling: the shape of things to come. Biochem. J. 339 Pt 3 (1999) 481-488
54. Daley W.P., Peters S.B., and Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J. Cell. Sci. 121 (2008) 255-264
55. Lock J.G., Wehrle-Haller B., and Stromblad S. Cell-matrix adhesion complexes: master control machinery of cell migration. Semin. Cancer Biol. 18 (2008) 65-76
56. Lukashev M.E., and Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8 (1998) 437-441
57. Rosso F., Giordano A., Barbarisi M., and Barbarisi A. From cell-ECM interactions to tissue engineering. J. Cell. Physiol. 199 (2004) 174-180
58. Snider P., Hinton R.B., Moreno-Rodriguez R.A., Wang J., Rogers R., Lindsley A., Li F., Ingram D.A., Menick D., Field L., Firulli A.B., Molkentin J.D., Markwald R., and Conway S.J. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ. Res. 102 (2008) 752-760
59. Ottani V., Martini D., Franchi M., Ruggeri A., and Raspanti M. Hierarchical structures in fibrillar collagens. Micron 33 (2002) 587-596
60. Bailey A.J., Sims T.J., Gabbiani G., Bazin S., and LeLous M. Collagen of Dupuytren's disease. Clin. Sci. Mol. Med. 53 (1977) 499-502
61. Berndt A., Kosmehl H., Katenkamp D., and Tauchmann V. Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology 62 (1994) 55-58
62. Satish L., Laframboise W.A., O'Gorman D.B., Johnson S., Janto B., Gan B.S., Baratz M.E., Hu F.Z., Post J.C., Ehrlich G.D., and Kathju S. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture. BMC Med. Genomics 1 (2008) 10
63. Brickley-Parsons D., Glimcher M.J., Smith R.J., Albin R., and Adams J.P. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J. Bone Joint Surg. [Am] 63 (1981) 787-797
64. Ehrlich H.P. The modulation of contraction of fibroblast populated collagen lattices by types I, II, and III collagen. Tissue Cell 20 (1988) 47-50
65. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., and Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev., Mol. Cell Biol. 3 (2002) 349-363
66. Shi-Wen X., Chen Y., Denton C.P., Eastwood M., Renzoni E.A., Bou-Gharios G., Pearson J.D., Dashwood M., du Bois R.M., Black C.M., Leask A., and Abraham D.J. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell 15 (2004) 2707-2719
67. Wynes M.W., Frankel S.K., and Riches D.W. IL-4-induced macrophage-derived IGF-I protects myofibroblasts from apoptosis following growth factor withdrawal. J. Leukoc. Biol. 76 (2004) 1019-1027
68. Horowitz J.C., Rogers D.S., Sharma V., Vittal R., White E.S., Cui Z., and Thannickal V.J. Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal 19 (2007) 761-771
69. Hinz B., Phan S.H., Thannickal V.J., Galli A., Bochaton-Piallat M.L., and Gabbiani G. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170 (2007) 1807-1816
70. Vi L., Njarlangattil A., Wu Y., Gan B.S., and O'Gorman D.B. Type-1 collagen differentially alters beta-catenin accumulation in primary Dupuytren's Disease cord and adjacent palmar fascia cells. BMC Musculoskelet. Disord. 10 (2009) 72
71. Grotendorst G.R., Rahmanie H., and Duncan M.R. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J. 18 (2004) 469-479
72. Darby I.A., and Hewitson T.D. Fibroblast differentiation in wound healing and fibrosis. Int. Rev. Cytol. 257 (2007) 143-179
73. Hinz B. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 127 (2007) 526-537
74. Hall P.N., Fitzgerald A., Sterne G.D., and Logan A.M. Skin replacement in Dupuytren's disease. J. Hand. Surg. [Br] 22 (1997) 193-197
75. Brotherston T.M., Balakrishnan C., Milner R.H., and Brown H.G. Long term follow-up of dermofasciectomy for Dupuytren's contracture. Br. J. Plast. Surg. 47 (1994) 440-443
76. Armstrong J.R., Hurren J.S., and Logan A.M. Dermofasciectomy in the management of Dupuytren's disease. J. Bone Joint Surg. Br. 82 (2000) 90-94
77. Howard J.C., Varallo V.M., Ross D.C., Roth J.H., Faber K.J., Alman B., and Gan B.S. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. BMC Musculoskelet. Disord. 4 (2003) 16